Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.50 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.49 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14860029 | 0.96 | CNR1 (0.52) | KCNK9RAPGEF3RAPGEF4PPARGNR1H4 | |
| SCHEMBL14860198 | 0.86 | KCNK3 (0.60) | KCNK9NR1H4NPC1RAB9AKCNK3 | |
| SCHEMBL14859726 | 0.86 | NLRP3 (0.55) | KCNK9NR1H4NPC1RAB9AKCNK3 | |
| SCHEMBL14860007 | 0.84 | KCNK9 (0.54) | KCNK9NR1H4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14859296 | 0.83 | NR1H4 (0.54) | NR1H4NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL14859781 | 0.82 | NPC1 (0.52) | KCNK9NPC1RAB9ACNR1KCNK3 | |
| SCHEMBL14860305 | 0.81 | SMARCA2 (0.45) | KCNK9NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL14859888 | 0.80 | NR1H4 (0.51) | RAPGEF3RAPGEF4NR1H4NPC1RAB9A | |
| SCHEMBL15149595 | 0.75 | KCNK9 (0.56) | KCNK9RAPGEF3RAPGEF4PPARGNR1H4 | |
| SCHEMBL2348633 | 0.75 | SMN1; SMN2 (0.65) | NPC1RAB9AKMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2583962-A2 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | claimed |
| EP-2583962-A2 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | UGP2, TPMT, UPP1 | KCNK9 3653/4885RAPGEF3 3959/4885RAPGEF4 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.